• 100mg capsules
• Approved for treating chronic lymphocytic leukaemia in adults in line with NICE

• 150mg capsules
• Approved as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults in line with NICE 
• Approved as an option for the adjuvant treatment of stage 1B (tumours 4 cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) after complete tumour resection in adults in line with NICE 

• 20mg and 40mg tablets
• Approved as an option for treating chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia without a T315I mutation after 2 or more tyrosine kinase inhibitors in adults, in line with NICE

• 840mg/14ml & 1200mg/20m concentrate for solution for infusion (IV)
• 1875mg/15ml solution for injection (S/C)
• Approved for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑positive tumour).  
• Approved in combination with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (HCC) in adults who have not had previous systemic treatment in line with NICE
• Approved for the treatment of advanced non-small-cell lung cancer in line with NICE
• Approved for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable in line with NICE
• Approved for adjuvant treatment of resected non-small-cell lung cancer in adults in line with NICE
• Approved with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults in line with NICE
• Approved with nab‑paclitaxel for triple-negative, unresectable, PD‑L1‑positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease in line with NICE
• Approved for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable in line with NICE

• Infusion
• Approved as an option for treating adenosine deaminase deficiency–severe combined immunodeficiency (ADA–SCID) when no suitable human leukocyte antigen-matched related stem cell donor is available in line with NICE.

• 25mg, 50mg, 100mg, 200mg, 300mg film coated tablets
•  Approved as an option for treating advanced systemic mastocytosis (including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm and mast cell leukaemia) in adults in line with NICE.

• 0.4 – 2 × 10⁸ cells dispersion for infusion

• 40 mg film-coated tablets
• Approved with managed access as an option for treating von Hippel-Lindau (VHL) disease in adults in line with NICE

• 0.4 – 2 × 10⁸ cells dispersion for infusion

• 160 mg, 200 mg film coated tablets
• Approved for treating hormone receptor (HR)‑positive HER2‑negative (defined as immunohistochemistry [IHC]0 or IHC1 positive, or IHC2 positive and in situ hybridisation [ISH]1 negative) locally advanced or metastatic breast cancer in adults in line with NICE

• Approved for use in previously treated multiple myeloma in line with NICE and NHSE Commissioning Policy
• Approved in combination with dexamethasone and lenalidomide for previously treated multiple myeloma in line with NICE

• Approved for treating metastatic or locally advanced cutaneous squamous cell carcinoma in adults in line with NICE

160 micrograms/g gel

Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:

NICE TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma

Commissioner: NHS England

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm.

• Approved as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults in line with NICE

• Approved in combination with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable in line with NICE
• Approved as an option for treating relapsed and refractory multiple myeloma in adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment in line with NICE
• Approved with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable in line with NICE and NHSE Specialised Commissioning guidance
• Approved in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis in line with NICE and NHSE Specialised Commissioning Guidance

• 20mg/4.5mL concentrate for solution for infusion 
• Approved for the treatment of high-risk neuroblastoma in people aged 12 months and over in line with NICE

• 500mg/10ml concentrate for solution for infusion
• Approved for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy in line with NICE
• Approved with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults in line with NICE
• Approved as an option to treat primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults when systemic therapy is suitable in line with NICE

• Approved for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults in line with NICE.
• Approved in combination with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer in line with NICE and NHS England Specialised Commissioning Policy.
• Approved as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung cancer (NSCLC) in adults in line with NICE
• Approved for untreated extensive-stage small-cell lung cancer in adults in line with NICE

• 40 mg/mL solution for injection
• Approved for treating relapsed and refractory multiple myeloma after 3 or more treatments in line with NICE
  
  

• Approved for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors in line with NICE

• 4mg/0.8ml & 48mg/0.8ml solution for injection 
• Approved for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments in line with NICE

• 3 mg, 4 mg, 5 mg film-coated tablets
• Approved for treating unresectable or metastatic urothelial cancer with susceptible FGFR3 genetic alterations in adults after at least 1 line of treatment for unresectable or metastatic cancer that included a PD‑1 or PD‑L1 inhibitor in line with NICE

• Approved for the treatment of locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens  in accordance with NICE and NHS England Commissioning Policy

• 100 mg hard capsules
• Approved as an option for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in line with NICE

100mg and 150mg film-coated tablets

Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:

• NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia

Commissioner: NHS England

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm

• 1mg, 5mg capsules
• Approved for previously treated metastatic colorectal cancer in line with NICE

• 4 mg film-coated tablets
• Approved for treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement in line with NICE

•  Approved for untreated acute myeloid leukaemia in line with NICE

• Approved for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults in line with NICE

• 2.5mg and 10mg concentrate for solution for infusion
• Approved for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments in line with NICE and NHSE Specialised Commissioning guidance

• Approved in combination with rituximab for the treatment of:
  
  • Untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation; NICE or
  • Chronic lympocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months NICE.

• 11mg powder for concentrate for solution for infusion
• Approved for desensitisation treatment before kidney transplant in people with chronic kidney disease in line with NICE and NHSE Commissioning Policy

• Approved for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults in line with NICE

20mg/mL concentrate for solution for infusion.

Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:

• NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

Not approved in accordance with the following NICE TAs:

• NICE TA727: Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)

Commissioner: NHS England

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm.

• 250mg tablets
• Approved for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments in line with NICE and NHSE Specialised Commissioning Policy.
• Approved for untreated acute myeloid leukaemia with an IDH1 R132 mutation in line with NICE
  
  

• Capsules: 2.3mg, 3mg, 4mg

20 mg/mL oral solution

• CD8+ and CD4+ cells 1.1-70 × 10⁶ cells/mL / 1.1-70 × 10⁶ cells/mL dispersion for infusion
• Approved (in line with NICE) for treating large B‑cell lymphoma that is refractory to, or has relapsed within 12 months after, first-line chemoimmunotherapy in adults with:
  • diffuse large B‑cell lymphoma
  • high-grade B‑cell lymphoma
  • primary mediastinal large B-cell lymphoma, or
  • follicular lymphoma grade 3B.

• 10mg powder for concentrate for solution for infusion
• Approved or treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments in line with NICE and NHSE Specialised Commissioning Policy

• Approved for previously treated ALK-positive advanced non-small-cell lung cancer in adults in line with NICE

• Lutetium (177Lu) oxodotreotide (Lutathera)
  • Approved for treating unresectable or metastatic neuroendocrine tumours in adults in line with NICE
• Lutetium-177 vipivotide tetraxetan (Pluvicto)
  • Approved for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults in line with NICE 

• Approved for the treatment of advanced systemic mastocytosis in line with NICE

• Approved for previously treated mycosis fungoides and Sézary syndrome in line with NICE

• 100mg, 150mg and 200mg tablets
• Approved for treating myelofibrosis-related splenomegaly or symptoms in adults in line with NICE

• Approved for the treatment of early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab in line with NHS England Commissioning Policy and NICE

• Approved for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults in line with NICE

• For the treatment of locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) after prior chemotherapy in adults.
• Approved for the treatment of advanced (unresectable or metastatic) melanoma in adults in line with NICE.
• Approved in combination with ipilimumab for treating advanced melanoma in line with NICE and NHS England Commissioning Policy (SSC1664)
• Approved for the treatment of advanced renal cell carcinoma in adults in line with NICE and NHS England Commissioning Policy
• Approved for the treatment of relapsed of refractory classical Hodgkin lymphoma in line with NICE and NHS England Commissioning Policy 
• Approved for the treatment of  locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy in line with NICE
• Approved for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in adults
• Approved for use in patients with previously untreated unresectable advanced or recurrent oesophageal cancer in line with NICE
• Approved in combination ipilimumab for use in patients with previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in line with NICE
• Approved for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults in line with NICE
• Approved adjuvant treatment of completely resected oesophageal or gastro‑oesophageal junction cancer in adults who have residual disease after previous neoadjuvant chemoradiotherapy in line with NICE
• Approved in combination with ipilimumab for untreated advanced renal cell carcinoma in line with NICE
• Approved for adjuvant treatment of invasive urothelial cancer at high risk of recurrence in line with NICE
• Approved with ipilimumab or untreated unresectable malignant pleural mesothelioma in adults in line with NICE
• Approved for treating locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy in line with NICE
• Approved (with fluoropyrimidine-based and platinum-based combination chemotherapy) for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults whose tumours express PD‑L1 at a level of 1% or more.
• Approved as an option for the neoadjuvant treatment of resectable (tumours at least 4 cm or node positive) non-small-cell lung cancer (NSCLC) in adults - in line with NICE TA876.
• Approved with cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults
• Approved for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults in line with NICE

• 240mg/20ml (12mg/1ml) & 80mg/20ml (4mg/1ml) concentrate for solution for infusion
• Approved for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over in line with NICE

• Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy in line with NICE.
• Approved for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation in line with NICE
• Approved for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults in line with NICE
• Approved for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults in line with NICE
• Approved as maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults in line with NICE and NHSE Specialised Commissioning policy
• Approved with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults in line with NICE and NHSE Specialised Commissioning policy
• Approved with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults in line with NICE
• Approved for maintenance treatment of BRCA muatation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
• Approved for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in line with NICE

• Approved in combination with bortezomib and dexamethasone as an option for the treatment of multiple myeloma in line with NICE.

• Approved for the treatment of advanced melanoma after disease progression with ipilimumab in accordance with NICE.  
• Approved for the treatment of advanced melanoma not previously treated with ipilimumab in accordance with NICE. 
• Approved for treating PD-L1-positive non-small-cell lung cancer 
• Approved for treating PD-L1-positive metastatic non-small-cell lung cancer 
• Approved for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more in line with NICE
• Approved with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.
• Approved for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults in line with NICE
• Approved for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in line with NICE
• Approved with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults in line with NICE
• Approved for adjuvant treatment of completely resected stage 3 melanoma in line with NICE
• Approved in combination with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer in line with NICE
• Approved for treating relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies in line with NICE
• Approved with paclitaxel or nab‑paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease in line with NICE
• Approved for adjuvant treatment of renal cell carcinoma in adults in line with NICE
• Approved for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over in line with NICE
• Approved with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations in line with NICE
• Approved plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults in line with NICE
• Approved with lenvatinib for previously treated advanced or recurrent endometrial cancer in line with NICE and NHSE Specialised Commissioning guidance
• Approved for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults in line with NICE and NHSE Specialised Commissioning guidance
• Approved plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in line with NICE
• Approved for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over in line with NICE
• Approved for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in line with NICE
• Approved for neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for resectable non-small-cell lung cancer (NSCLC) with a high risk of recurrence in adults in line with NICE.
• Approved for the adjuvant treatment of non-small-cell lung cancer (NSCLC) with a high risk of recurrence after complete resection and platinum-based chemotherapy in adults in line with NICE

• Approved with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant in line with NICE
• Approved with rituximab, cyclophosphamide, doxorubicin and prednisolone (R‑CHP) for untreated diffuse large B-cell lymphoma (DLBCL) in adults - in line with NICE TA874.

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm

• 17.7mg, 26.5mg film coated tablets
• Approved as an option for newly diagnosed FLT3‑ITD‑positive acute myeloid leukaemia (AML) in adults in line with NICE

• 200mg, 250mg, 300mg film coated tablets
• Approved for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults in line with NICE
• Approved for the maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy in adults in line with NICE

• 180mg powder for solution for infusion

• 20mg tablets
• Approved with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments in adults in line with NICE
• Approved with bortezomib and dexamethasone for previously treated multiple myeloma in adults in line with NICE

• 40mg and 80mg capsules
• Approved for advanced thyroid cancer with RET alterations in people 12 years and older in line with NICE
• Approved for untreated RET fusion-positive advanced non-small-cell lung cancer in adults in line with NICE
• Approved (in line with NICE) for treating:
  • advanced RET fusion-positive thyroid cancer that is refractory to radioactive iodine (if radioactive iodine is appropriate), only if systemic treatment is needed after sorafenib or lenvatinib
  • advanced RET-mutant medullary thyroid cancer, only if systemic treatment is needed after cabozantinib or vandetanib.
• Approved (in line with NICE) for treating:
  • advanced RET fusion-positive thyroid cancer that is refractory to radioactive iodine (if radioactive iodine is appropriate)
  • advanced RET-mutant medullary thyroid cancer.
• Approved for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in line with NICE

• 10mg and 35mg hard capsules
• Approved treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over in line with NICE

Tablets: 120 mg

• 0.25mg and 1mg capsule
• Approved or HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults in line with NICE

• Approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy (SSC1679).

• 200 micrograms/ mL concentrate for solution for infusion
• Approved for treating advanced uveal melanoma in line with NICE

• 10 mg/mL, 90 mg/mL solution for injection
• Approved as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on the last treatment in line with NICE.

• Approved for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under in line with NICE
• Will be funded by NHS England at the following commissioned centres: Newcastle University Teaching Hospitals, Leeds Teaching Hospitals, Sheffield Teaching Hospitals.

• Capsules: 890 mg and 1340 mg

Vial: powder for concentrate for infusion, 100 mg

• Approved in combination with rituximab for treating chronic lymphocytic leukaemia in adults who have had at least 1 previous therapy in line with NICE
• Approved in combination with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable in line with NICE
• Approved in combination with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable in line with NICE.
• Approved for the treatment of chronic lymphocytic leukaemia in adults:
  • with a 17p deletion or TP53 mutation and when a B‑cell receptor pathway inhibitor is unsuitable, or whose disease has progressed after a B‑cell receptor pathway inhibitor or
  • without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo‑immunotherapy and a B‑cell receptor pathway inhibitor in line with NICE

• Named patient supply only.

• Not Recommended for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in adults in line with NICE

• Treating relapsed and frefractory multuiple myeloma after 3 or more treatments

• Not approved for for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)

• 1mg/1ml and 30mg/30ml concentrate for solution for infusion
• Mosunetuzumab is not recommended for treating relapsed or refractory follicular lymphoma in adults who have had 2 or more systemic therapies in line with NICE.

• Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)
• Not recommended in line with NICE: Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma

• 50mg tablet
• Ripretinib is not recommended for treating advanced gastrointestinal stromal tumour (GIST) in adults after 3 or more kinase inhibitors, including imatinib, in line with NICE.

• 200mg powder for concentrate for solution for infusion
• Tafasitamab with lenalidomide is not recommended for treating relapsed or refractory diffuse large B‑cell lymphoma in adults who cannot have an autologous stem cell transplant in line with NICE

• Treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies.

• Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
• Not approved for treating HER2-low metastatic or unresectable breast cancer after chemotherapy in line with NICE

• 100 mg powder for concentrate for solution for infusion 
• Not Recommended for untreated, locally advanced, unresectable or metastatic, claudin-18.2-positive, HER2-negative, gastric or gastro-oesophageal junction adenocarcinoma in adults in line with NICE